Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-1 Therapy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT06964568
What this trial is testing

CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC

Who this might be right for
Esophageal CarcinomaRadiotherapyImmunotherapy
Fudan University 452
Very early researchStudy completedNCT03153410
What this trial is testing

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

Who this might be right for
Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 11
Testing effectiveness (Phase 2)UnknownNCT06304987
What this trial is testing

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Who this might be right for
Locally Advanced Rectal Cancer
Beijing Friendship Hospital 50
Large-scale testing (Phase 3)Study completedNCT03764293
What this trial is testing

Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Who this might be right for
Locally Advanced or Metastatic and Unresectable HCC
Jiangsu HengRui Medicine Co., Ltd. 543
Early research (Phase 1)Active Not RecruitingNCT05640193
What this trial is testing

LN-144 in People With Metastatic Melanoma to the Brain

Who this might be right for
Metastatic Melanoma
Memorial Sloan Kettering Cancer Center 10
Large-scale testing (Phase 3)Study completedNCT03142334
What this trial is testing

Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

Who this might be right for
Renal Cell Carcinoma
Merck Sharp & Dohme LLC 994
Testing effectiveness (Phase 2)UnknownNCT04542369
What this trial is testing

Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer

Who this might be right for
Small-cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 15
Not applicableLooking for participantsNCT06752044
What this trial is testing

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

Who this might be right for
Advanced NSCLC
The First Affiliated Hospital of Nanchang University 10
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06888037
What this trial is testing

Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer

Who this might be right for
Gastric AdenocarcinomaGEJ AdenocarcinomaFirst-line Therapy+3 more
Ruijin Hospital 55
Early research (Phase 1)UnknownNCT04906044
What this trial is testing

Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer

Who this might be right for
TislelizumabLocally Advanced Rectal CancerTotal Neoadjuvant Treatment+1 more
The First Hospital of Jilin University 46
Testing effectiveness (Phase 2)UnknownNCT04984018
What this trial is testing

Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

Who this might be right for
Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University 73
Early research (Phase 1)Looking for participantsNCT07619313
What this trial is testing

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

Who this might be right for
Borderline Resectable Pancreatic Ductal AdenocarcinomaLocally Advanced CholangiocarcinomaLocally Advanced Pancreatic Adenocarcinoma+5 more
Jonsson Comprehensive Cancer Center 46
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06166589
What this trial is testing

Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer

Who this might be right for
Previously AG Chemotherapy Treated Pancreatic Cancer
Shanghai Zhongshan Hospital 19
Testing effectiveness (Phase 2)Study completedNCT04508803
What this trial is testing

Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer

Who this might be right for
Treatment Efficacy
Fudan University 37
Testing effectiveness (Phase 2)UnknownNCT06375486
What this trial is testing

Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.

Who this might be right for
Hepatocellular Carcinoma Non-resectableHepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06946836
What this trial is testing

Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study

Who this might be right for
Resectable Non-small Cell Lung CancerBispecific AntibodyNeoadjuvant Therapy
Shanghai Pulmonary Hospital, Shanghai, China 80
Testing effectiveness (Phase 2)Study completedNCT02423863
What this trial is testing

In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®

Who this might be right for
MelanomaHead and Neck CancerSarcoma+1 more
Oncovir, Inc. 26
Not applicableStudy completedNCT03197636
What this trial is testing

Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients

Who this might be right for
Malignant Melanoma
Aarhus University Hospital 40
Testing effectiveness (Phase 2)UnknownNCT06509971
What this trial is testing

QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Recurrent Ovarian Cancer
West China Second University Hospital 39
Testing effectiveness (Phase 2)Active Not RecruitingNCT04080804
What this trial is testing

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Who this might be right for
Head and Neck Squamous Cell Carcinoma (HNSCC)
Dan Zandberg 80
Next Page